Conclusions: Compared to CR, VMAT greatly improves conformity and reduces mean dose and dose delivered from 20 Gy and higher to the lungs and the body.These results led us to plan a new dosimetric comparison between VMAT and Helical Tomotherapy. This will be the subject of a forthcoming study.
Conclusions: TD has demonstrated to be a feasible and efficient mean to deliver accelerated hypofractionated adjuvant radiation in EBC patients after conserving surgery, with an optimal dose distribution, negligible toxicity and encouraging clinical results. This technical solution is a valid IMRT option for breast radiation treatment.
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Dosimetric comparison of 3DCRT, IMRT and Carotid sparing IMRT in breast cancer patients P. Erpolat 1 , M. Akmansu 1 , S. Catli 1 , K. Akkan 2 , H. Bora 1 1 Gazi Üniv. Tip Fakültesi, Radiation Oncology, Ankara, Turkey 2 Gazi Üniv. Tip Fakültesi, Radiology, Ankara, Turkey Purpose/Objective: The proximal carotid artery is often included within a supraclavicular RT field in patients with node-positive disease. It is rational that these patients have a greater risk of cerebrovascular events, which has been shown after head and neck irradiation. The purpose of our study was to determine the radiation doses to carotid artery among three dimensional conformal radiotherapy (3DCRT) and intensity modulated radiotherapy (IMRT) and to perform carotid sparing intensity modulated radiotherapy (CS-IMRT) without compromising target volume coverage. Materials and Methods: Ten patients who were treated with comprehensive 3DCRT were selected. DICOM data were used to create virtual IMRT and CS-IMRT plans. The carotid artery was retrospectively contoured. The inverse planning for IMRT was constituted and 5-field beam arrangement was used. The optimization objectives of the CTV, PTV and organ at risks were defined as used for 3DCRT. The dose constraints for organ at risk were as follows: V20<20% for ipsilateral lung; V30<10% for heart;V10 for contralateral lung; V10 for contralateral breast; 50 Gy for ipsilateral brachial plexus. For CS-IMRT, V35 for ipsilateral carotid artery was additionally defined. The prescription dose was 50 Gy at 2 Gy per fraction for three planning. ≥95% of the PTV received 100% of the prescription dose. The parameters used for comparison of planning were V20 for ipsilateral lung; V30 for heart, V10 for contralateral lung; V10 for contralateral breast,mean, and median maximum dose along with V35 and V50 for carotid artery. Results: There was a difference in terms of HI and CI among the three treatment plans. After pairwise comparison; 3DCRT plans had greater HI and had less CI than IMRT and CS-IMRT planings.3DCRT plans had significantly higher percentages of V20 ipsilateral lung volume and had significantly lower percentages of V10 contralateral lung volume compared to IMRT and CS-IMRT planings. Although no difference for V20 ipsilateral lung was observed between IMRT plans, the percentage of V10 contralateral lung was lower in the CS-IMRT plans compared to IMRT plans. Carotid artery doses were significantly increased with IMRT compared to 3DCRT plans. With 3DCRT planning, V35 and V50 were 57.5% and 12.65%. With IMRT planning, V35 and V50 were increased to 63.5%and 44% (p<0.005). After application of dose constraints to the carotid arteries, these parameters were found as 61% and 0% in CS-IMRT planning without compromising target volume coverage. The results of dose parameters for planning were summarized in Table 1 .
2nd ESTRO Forum 2013 S395 Conclusions: IMRT planning achieves better dose coverage and homogeneity in comprehensive irradiation in breast cancer; however, it increases dose to carotid artery as compared to conventional 3DCRT. Byspecifying dose constraint to the carotid artery, it is possible to reduce carotid artery doses in IMRT plans by improving dose conformity and homogeneity. It seems reasonable to designate carotid artery as a dose limited structure for long term survivors with high risks for vascular disorders.
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Acute and late toxicity with hypofractionated radiation therapy for early breast cancer compared to conventional RT A. Podgornii 1 , M. Galeandro 1 , D. Ramundo 1 , F. Vigo 1 , R. Micera 1 , E. Cagni 1 , C. Bassi 1 , C. Iotti 1 , P. Ciammella 1 1 Arcispedale S. Maria Nuova, Advanced thecnologies, Reggio Emilia, Italy Purpose/Objective: The purpose of the present study is to evaluate toxicity and cosmetic outcome in breast cancer survivors treated with hypo-fractionated adjuvant radiotherapy (HF-RT) and to identify risk factors for toxicity, with special focus on the impact of age, co morbidities and chemotherapy. For comparison, a group of 65 patients with similar characteristics and consecutively treated with conventional fractionation was retrospectively selected. Materials and Methods: From April 2010 and May 2012, 190 women with early breast cancer were treated with HF-RT, after conserving surgery. The patients received 40.05 Gy in 15 fractions. The boost to the tumour bed was administered with a total dose of 9 Gy in 3 consecutive fractions in 50 women due to young age (< 50 yrs) or to positive margins. Physician-rated toxicity and cosmetic outcomes were prospectively assessed during yearly follow-up after radiotherapy. Results: In the HF-RT group, the mean age was 69 years. 11% and 32% patients were affected by diabetes mellitus and hypertension, respectively. 13% had tumors that were 2 cm or larger in diameter; pTis = 17%, pT1a= 6%, pT1b= 23%, pT1c=41%, pT2=13% ; 10% had estrogen-receptor-negative disease and 29 % had high-grade disease. Pre-operative chemotherapy was administered in 10 patients; adjuvant systemic therapy and hormone therapy were given in 19 patients, while 11 and 115 patients received chemotherapy or hormone therapy alone, respectively. The mean follow-up was 19 months (range 6-32 months). The median time from surgery was 29 days, with overall median treatment duration of 22 days. At last follow up all patients are alive without local recurrence. By the end of RT 18% of the patients treated with HF-RT developed no toxicity, while 55.7% showed grade 1 and 13.3% grade 2 acute skin toxicity. Only one patient experienced a grade 3 acute skin toxicity. In the control group, early G1 reactions were observed in 24 patients (42%); 19% of patients showed G2 acute toxicity and only one patient developed G3 acute reaction. Neither grade 4 skin ulceration nor soft tissue necrosis was observed. Late toxicity was assessed after 6 months from RT completion in 120/190 patients in the hypofractionation group and in 51/65 patients in the standard RT group. Late toxicity according to the RTOG criteria was observed in 9 patients (7.5%) in the HF-RT group and in 4 patients (8%) in the conventional fractionated radiation group. The difference was not statistically significant. Cosmetic result was assessed and scored at the RT end and 6 months later: at last follow up, 71% of women in the control-group as compared with 68.8% of the women in the HF-RT group had a good or excellent cosmetic outcome. Conclusions: Our results confirm the feasibility of the HF-RT with 2,67 Gy/fx to a total dose of 40,05 Gy in patients with breast cancer. If compared with conventional RT group, the hypofractionation not seems to increase the late toxicity. Long-term follow up is need to confirm this finding.
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